Bioventus Inc (OQ:BVS)
Business Focus: Medical Equipment
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703 |
| Tel: | N/A |
| Website: | https://www.bioventus.com |
| IR: | See website |
| Key People | ||
| Robert E. Claypoole President, Chief Executive Officer, Director | Mark Singleton Chief Financial Officer, Senior Vice President | Katrina Church Senior Vice President, Chief Compliance Officer |
| Anthony D'adamio Senior Vice President, General Counsel | Sharon W. Klugewicz Senior Vice President - Quality and Regulatory Affairs | |
| Business Overview |
| Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body's natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders. |
| Financial Overview |
| For the nine months ended 30 September 2023, Bioventus Inc revenues decreased 2% to $376.9M. Net loss before extraordinary items increased less than 1% to $90.6M. Revenues reflect U.S. segment decrease of 5% to $331.1M. Net income reflects Impairment of assets decrease of 37% to $78.6M (expense), Selling, general ane expe decrease of 10% to $219.3M (expense). |
| Employees: | 970 as of Sep 30, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $696.33M as of Dec 31, 2023 |
| Annual revenue (TTM): | $502.76M as of Dec 31, 2023 |
| EBITDA (TTM): | $90.95M as of Dec 31, 2023 |
| Net annual income (TTM): | -$122.57M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$0.18M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $367.79M as of Dec 31, 2023 |
| Shares outstanding: | 79,165,540 as of Feb 27, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.